CAR T-cell Availability for Multiple Myeloma Improving but Still Limited.

A 2022 survey found that only about 25% of patients with multiple myeloma who were waiting for CAR T-cell therapy received the treatment. Manufacturing bottlenecks, such as shortages of viral vectors, limited supply. New approaches for manufacturing and testing the cells could improve their availability, but demand could also soar if they are approved for earlier use in treatment regimens.